These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 29763833)

  • 1. β2-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases.
    Matera MG; Page C; Rinaldi B
    Curr Opin Pharmacol; 2018 Jun; 40():142-146. PubMed ID: 29763833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pepducins as a potential treatment strategy for asthma and COPD.
    Panettieri RA; Pera T; Liggett SB; Benovic JL; Penn RB
    Curr Opin Pharmacol; 2018 Jun; 40():120-125. PubMed ID: 29729548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy.
    Calzetta L; Matera MG; Cazzola M
    Curr Opin Pharmacol; 2018 Jun; 40():95-103. PubMed ID: 29626716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome.
    Lee SY; Park HY; Kim EK; Lim SY; Rhee CK; Hwang YI; Oh YM; Lee SD; Park YB
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2797-2803. PubMed ID: 27877033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
    Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-adrenoceptor responses of the airways: for better or worse?
    Broadley KJ
    Eur J Pharmacol; 2006 Mar; 533(1-3):15-27. PubMed ID: 16469310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
    Calzetta L; Matera MG; Cazzola M
    Eur J Pharmacol; 2015 Aug; 761():168-73. PubMed ID: 25981302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
    Sin DD; Man SF
    Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β
    De Pascali F; Ippolito M; Wolfe E; Komolov KE; Hopfinger N; Lemenze D; Kim N; Armen RS; An SS; Scott CP; Benovic JL
    Br J Pharmacol; 2022 Oct; 179(19):4692-4708. PubMed ID: 35732075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways.
    Cooper PR; Panettieri RA
    J Allergy Clin Immunol; 2008 Oct; 122(4):734-740. PubMed ID: 18774166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research and development of bronchodilators for asthma and COPD with a focus on G protein/KCa channel linkage and β2-adrenergic intrinsic efficacy.
    Kume H; Fukunaga K; Oguma T
    Pharmacol Ther; 2015 Dec; 156():75-89. PubMed ID: 26432616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.
    Ding B; Small M
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and novel bronchodilators in respiratory disease.
    Spina D
    Curr Opin Pulm Med; 2014 Jan; 20(1):73-86. PubMed ID: 24247039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods.
    Kwak MS; Kim E; Jang EJ; Kim HJ; Lee CH
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2365-76. PubMed ID: 26604734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond the dogma: novel beta2-adrenoceptor signalling in the airways.
    Giembycz MA; Newton R
    Eur Respir J; 2006 Jun; 27(6):1286-306. PubMed ID: 16772391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review.
    Lopez-Campos JL; Calero-Acuña C; Márquez-Martín E; Quintana Gallego E; Carrasco-Hernández L; Abad Arranz M; Ortega Ruiz F
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1867-1876. PubMed ID: 28694697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
    Casarosa P; Kollak I; Kiechle T; Ostermann A; Schnapp A; Kiesling R; Pieper M; Sieger P; Gantner F
    J Pharmacol Exp Ther; 2011 Jun; 337(3):600-9. PubMed ID: 21357659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR2 activation causes tachyphylaxis to β2 -agonists in vitro and ex vivo: modelling bacterial exacerbation.
    Alkhouri H; Rumzhum NN; Rahman MM; FitzPatrick M; de Pedro M; Oliver BG; Bourke JE; Ammit AJ
    Allergy; 2014 Sep; 69(9):1215-22. PubMed ID: 24862376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cAMP regulation of airway smooth muscle function.
    Billington CK; Ojo OO; Penn RB; Ito S
    Pulm Pharmacol Ther; 2013 Feb; 26(1):112-20. PubMed ID: 22634112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.